Ratings by Evercore ISI (Cory Kasimov)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/12/2026 | Benitec BioPharma | BNTC | New Coverage | Outperform (N/A) |
12.08 (12.31) |
1.9% | Details | |
| 5/8/2026 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2026 | Scholar Rock | SRRK | New Coverage | Outperform (N/A) |
47.14 (55.89) |
18.56% | Details | |
| 5/5/2026 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/14/2026 | Revolution | RVMD | Maintain | Outperform (N/A) |
|
Details | ||
| 4/1/2026 | Cytokinetics | CYTK | Maintain | Outperform (N/A) |
|
Details | ||
| 3/27/2026 | Upstream Bio | UPB | Downgrade | In Line (Outperform) |
9.79 (6.55) |
-33.09% | Details | |
| 2/26/2026 | Edgewise Therapeutics | EWTX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/24/2026 | Vir Biotechnology | VIR | Maintain | Outperform (N/A) |
|
Details | ||
| 2/23/2026 | Arcellx Inc. | ACLX | Downgrade | In Line (Outperform) |
64.11 (115.07) |
79.49% | Details | |
| 2/17/2026 | Moderna | MRNA | Maintain | In Line (N/A) |
|
Details | ||
| 2/13/2026 | Alnylam Pharmaceuticals | ALNY | Maintain | Outperform (N/A) |
|
Details | ||
| 1/23/2026 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/22/2026 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/16/2025 | Immunome Inc. | IMNM | Maintain | Outperform (N/A) |
|
Details | ||
| 11/20/2025 | ORIC Pharmaceuticals | ORIC | New Coverage | Outperform (N/A) |
11.90 (12.89) |
8.32% | Details | |
| 11/18/2025 | Upstream Bio | UPB | New Coverage | Outperform (N/A) |
24.53 (9.79) |
-60.09% | Details | |
| 10/27/2025 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 9/3/2025 | Vir Biotechnology | VIR | New Coverage | Outperform (N/A) |
5.00 (11.63) |
132.6% | Details | |
| 8/25/2025 | Vertex | VRTX | New Coverage | Outperform (N/A) |
395.12 (547.65) |
38.6% | Details | |
| 8/25/2025 | Alnylam Pharmaceuticals | ALNY | New Coverage | Outperform (N/A) |
454.38 (246.11) |
-45.84% | Details | |
| 8/12/2025 | Summit Therapeutics plc | SMMT | Maintain | Outperform (N/A) |
|
Details | ||
| 8/7/2025 | Edgewise Therapeutics | EWTX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/4/2025 | BioNTech | BNTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/16/2025 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2025 | Xenon Pharmaceuticals | XENE | New Coverage | Outperform (N/A) |
29.60 (60.00) |
102.7% | Details | |
| 5/7/2025 | Cytokinetics | CYTK | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2025 | Neurocrine Bio. | NBIX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/28/2025 | Spring Works Therapeutics | SWTX | Downgrade | In Line (Outperform) |
44.72 (46.99) |
5.08% | Details | |
| 3/12/2025 | Summit Therapeutics plc | SMMT | New Coverage | Outperform (N/A) |
18.50 (14.16) |
-23.46% | Details | |
| 1/27/2025 | Moderna | MRNA | Maintain | In Line (N/A) |
|
Details | ||
| 12/16/2024 | Edgewise Therapeutics | EWTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/22/2024 | Edgewise Therapeutics | EWTX | New Coverage | Outperform (N/A) |
31.98 (42.25) |
32.11% | Details | |
| 11/20/2024 | Spring Works Therapeutics | SWTX | New Coverage | Outperform (N/A) |
37.93 (46.99) |
23.89% | Details | |
| 11/19/2024 | BioNTech | BNTX | Upgrade | Outperform (In Line) |
101.87 (101.95) |
0.08% | Details | |
| 10/31/2024 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 10/29/2024 | Arcellx Inc. | ACLX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/24/2024 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 9/12/2024 | Moderna | MRNA | Maintain | In Line (N/A) |
|
Details | ||
| 8/6/2024 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 6/24/2024 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2024 | Arcellx Inc. | ACLX | New Coverage | Outperform (N/A) |
49.74 (64.11) |
28.89% | Details | |
| 5/14/2024 | Neurocrine Bio. | NBIX | New Coverage | Outperform (N/A) |
136.70 (156.76) |
14.67% | Details | |
| 5/14/2024 | BridgeBio Pharma | BBIO | New Coverage | Outperform (N/A) |
29.10 (76.57) |
163.13% | Details | |
| 5/14/2024 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Outperform (N/A) |
81.03 (64.84) |
-19.98% | Details | |
| 5/14/2024 | BioNTech | BNTX | New Coverage | In Line (N/A) |
91.67 (101.87) |
11.13% | Details | |
| 5/14/2024 | Moderna | MRNA | New Coverage | In Line (N/A) |
117.31 (154.27) |
31.51% | Details | |
| 5/14/2024 | Regeneron Pharma | REGN | New Coverage | Outperform (N/A) |
973.80 (823.82) |
-15.4% | Details |
